Citadel Securities Maintains a 'Neutral' on United Therapeutics (UTHR); Tyvaso Growth Returns, but We Remain Cautious Ahead of FREEDOM-C2 Data

Go back to Citadel Securities Maintains a 'Neutral' on United Therapeutics (UTHR); Tyvaso Growth Returns, but We Remain Cautious Ahead of FREEDOM-C2 Data